<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/BA5EEAB8-7AAC-4C1C-B2AF-42BF056D13BA"><gtr:id>BA5EEAB8-7AAC-4C1C-B2AF-42BF056D13BA</gtr:id><gtr:name>Green Biologics Limited</gtr:name><gtr:address><gtr:line1>45A WESTERN AVENUE , MILTON PARK</gtr:line1><gtr:city>ABINGDON</gtr:city><gtr:postCode>OX14 4RU</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BA5EEAB8-7AAC-4C1C-B2AF-42BF056D13BA" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>BA5EEAB8-7AAC-4C1C-B2AF-42BF056D13BA</gtr:id><gtr:name>Green Biologics Limited</gtr:name><gtr:address><gtr:line1>45A WESTERN AVENUE , MILTON PARK</gtr:line1><gtr:city>ABINGDON</gtr:city><gtr:postCode>OX14 4RU</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>153120.0</gtr:offerGrant><gtr:projectCost>204160.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8C15A59E-F270-4A96-A6B9-32FD3436DF37" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>8C15A59E-F270-4A96-A6B9-32FD3436DF37</gtr:id><gtr:name>Lucite International UK Limited</gtr:name><gtr:address><gtr:line1>Cumberland House
15-17 Cumberland Place</gtr:line1><gtr:city>Southampton</gtr:city><gtr:postCode>SO15 2BG</gtr:postCode><gtr:region>South East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>13745.0</gtr:offerGrant><gtr:projectCost>21146.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0DF917B7-46B5-46F2-AF19-DE70627BE978"><gtr:id>0DF917B7-46B5-46F2-AF19-DE70627BE978</gtr:id><gtr:firstName>Liz</gtr:firstName><gtr:surname>Jenkinson</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131907"><gtr:id>A97E73D8-4FB7-43A4-83E6-5FCC975CE2F0</gtr:id><gtr:title>Clostridial on purpose acetone (COPA)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131907</gtr:grantReference><gtr:abstractText>There is large global demand for acetone for use as a solvent and in production of important chemicals and materials including transparent plastics such as methyl methacrylate (MMA). Acetone is currently produced by reacting petro-chemicals propylene and benzene, hence its price is volatile and the process is unsustainable. GBL are experts in clostridial (non-pathogenic) fermentation for production of the solvent n-butanol, which generates some acetone as a co-product. We (GBL and MMA-producer Lucite) undertook an InnovateUK business study to investigate potential for a process making solely acetone, and determined that this would be economically and technologically feasible. We want to use our expertise in clostridial biology to develop a strain of clostridia having high yield of acetone, necessary for the commercial process. Lucite will explore matters relating to use of bio-acetone for bio-MMA production.</gtr:abstractText><gtr:fund><gtr:end>2016-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>166865</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131907</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>